2026-03-19 12:35:12
Niagen Bioscience Increases Share Repurchase Program to $20 Million
Expected Stock impact: Slightly Positive
On March 19, 2026, Niagen Bioscience, Inc. announced an increase in its share repurchase program, raising the total authorization from $10 million to $20 million. This decision was made by the Board of Directors to provide additional flexibility in returning capital to stockholders and to repurchase shares at attractive prices, depending on market conditions. As of March 17, 2026, the company had already repurchased approximately $2.6 million of its common stock under the previous program. The share repurchase program allows the company to buy back shares from the open market or through privately negotiated transactions, subject to market conditions and applicable securities laws. The program is expected to remain in effect for a previously approved 24-month period unless modified or terminated earlier by the Board. CEO Rob Fried expressed confidence in the company's strategy and long-term value, stating that the increase reflects their conviction in the business's strength and the current market valuation of their stock. This move is anticipated to have a small positive effect on the stock price as it signals the company's commitment to enhancing shareholder value.
